Egyptian healthtech Reme-D raises Pre-Series A capital

Reme-D, an Egyptian healthtech company building molecular diagnostic tests, has closed a 1.45 million dollar Pre-Series A funding round led by Anara Impact Capital, with participation from Global Innovation Fund, Africa Health Ventures, and several other backers. The round marks a meaningful step up for a Cairo based startup that has spent the past three years quietly building out local manufacturing capacity for a category of medical technology that Africa has historically had to import. Founded in 2023 by Salma Tammam, Reme-D develops and manufactures molecular diagnostic tests for diseases including tuberculosis, HIV, hepatitis, and human papillomavirus, the last of which remains a leading cause of cervical cancer among women across the continent. The company's pitch centers on making these tests accurate, fast, affordable, and importantly, temperature resilient, a detail that matters enormously in regions where cold chain logistics and reliable laboratory infrastructure are far from guaranteed. Reme-D says it has already commercialized 30 diagnostic products and supplied more than 550,000 tests to customers across Egypt, Kenya, and Sudan, giving it a track record that likely made this round an easier sell to investors focused on measurable health impact. The new capital will go toward a tenfold expansion of the company's manufacturing capacity, along with pushing further into additional African markets and broadening its diagnostic product portfolio. Reme-D also plans to use part of the funding to develop new tests targeting genetic diseases and cancer, moving beyond its current focus on infectious disease diagnostics into more complex screening categories. This is not Reme-D's first outside capital either, having previously secured 500,000 dollars from the Global Innovation Fund to help scale its molecular diagnostics work, meaning this Pre-Series A effectively builds on a funder relationship that was already in place. Anara Impact Capital's Principal Mohamed Hussain framed the investment around the founder and the underlying thesis of local manufacturing, noting that Reme-D has already shown high quality molecular diagnostics can be developed and produced locally rather than relying on imported kits, and that the firm is backing the company to scale that impact across the Middle East, Africa, and beyond. That framing points to a broader shift playing out in African healthtech investing, where capital has spent the last decade heavily favoring digital health platforms, telemedicine apps, and health records systems, but is increasingly rotating toward companies building physical manufacturing capability for diagnostics, pharmaceuticals, and medical devices, a lesson many investors trace back to the supply chain disruptions of the pandemic years. Reme-D's work also carries a notable public health angle beyond its commercial diagnostics business. The company recently developed a custom solar powered mobile laboratory commissioned by the World Health Organization's Egypt office, a unit that supports the Egyptian Ministry of Health's efforts to monitor vector borne diseases in remote communities, a project that speaks to the kind of infrastructure gap Reme-D is positioning itself to fill well beyond standard retail diagnostics. For the wider MENA region, Reme-D's raise fits into a slower but steady pattern of healthtech investment activity spreading beyond the Gulf's usual hubs and into North Africa, where Egypt has built a reputation for producing capital efficient startups addressing infrastructure gaps rather than purely consumer facing apps. While Saudi Arabia and the UAE continue to dominate MENA's overall venture funding totals, largely through fintech, proptech, and gaming deals backed by sovereign wealth, Egypt's healthtech and biotech sector has quietly carved out its own niche, driven by companies solving problems specific to underserved populations across Africa rather than competing directly with Gulf focused startups. Investors like Anara Impact Capital and Africa Health Ventures, both of which specialize in health impact investing across the continent, represent a different funding channel than the sovereign wealth backed vehicles more commonly seen in Saudi and UAE deals, giving Egyptian founders in health and biotech access to capital pools that are shaped more by global health financing priorities than by regional economic diversification agendas. That distinction may end up mattering more as African and Gulf healthtech ecosystems continue to mature along somewhat different tracks, each drawing on its own mix of investors, mandates, and regional health priorities.